IHS Chemical Week

Chemical Week Magazine :: Other

Ranbaxy and GSK Enter R&D Agreement

1:57 PM MDT | July 30, 2007 | Deepti Ramesh

Ranbaxy Laboratories (Gurgaon), India’s biggest pharmaceuticals company, has signed a multiyear R&D agreement with GlaxoSmithKline (GSK). Ranbaxy could receive more than $100 million in milestone payments for a product it develops and is subsequently launched by GSK, in multiple indications and up to double-digit royalties on worldwide net sales, under the terms of the agreement. “GSK will be able to develop more products faster by collaborating with our R&D team, and Ranbaxy will benefit from GSK’s vast drug discovery and development...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa